Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Get instant loans payday loans no faxing in UK
Popular Articles
Cellulite Cream

Baltimore Churches Participate In Program Providing HIV Testing To Residents
Eleven Baltimore churches on Tuesday provided HIV testing to local residents as part of a larger effort by the JACQUES Initiative, a program at the University of Maryland School of Medicine"s Institute of Human Virology, the Baltimore Sun reports. The JACQUES Initiative launched Project SHALEM in partnership with the Maryland AIDS Administration and several local faith-based and community organizations, according to the Sun. Derek Spencer, the executive director of the JACQUES Initiative, said, "The ultimate goal is to make churches, mosques and synagogues a safe place where people can receive HIV support. We are no longer going to wait for people to come into our academic centers for help." He said organizers hoped to test 1,000 people, noting that at one of the testing sites, within the first hour, four people tested positive with the rapid oral swab tests. Angela Wakhweya, deputy director of the Maryland AIDS Administration, said the goal of the project is to eliminate new HIV cases in the state (Bass, 7/22).
generic viagra online
A Surprise 'Spark' For Pre-Cancerous Colon Polyps
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah studied the events leading to colon cancer and found that an unexpected protein serves as the "spark" that triggers formation of colon polyps, the precursors to cancerous tumors.
News of the day
Abbott Initiates Trial Of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes From SPIRIT Family Of Trials
Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company"s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States. The first patient was enrolled into the SPIRIT PRIME clinical trial at Hillcrest Medical Center in Tulsa, Okla., by Rajesh Chandwaney, M.D.
Diagnostics

Eurand Successfully Completes Registration Procedure For Paracetamol ODT 250 And 500 Mg In The European Union

Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed. In addition to The Netherlands, which acted as the reference member state, the DCP involved the United Kingdom, Germany, France, Italy and Spain. Formal approval is now expected from each country by the end of 2009. Eurand is actively seeking a partner to market and distribute Paracetamol ODT in these countries. Paracetamol (also known as acetaminophen) is a widely used analgesic (pain reliever) and antipyretic (fever reducer). Paracetamol ODT is indicated for symptomatic treatment of mild-to-moderate pain and/or fever. The 500 mg dose is indicated in adults and adolescents (over 12 years old) only, and the 250 mg dose is for use in children from the age of four and adolescents only. The product may be taken with or without liquid. "We are pleased by the Dutch MEB"s decision regarding our Paracetamol ODT, and we look forward to receiving approval in the six individual countries later this year," said GearÃöid Faherty, Chairman and Chief Executive Officer. "We believe our formulation will deliver this well-recognized pain reliever in a more patient friendly manner, particularly for those patients who have difficulty swallowing." He noted that this is the second ODT formulation that Eurand has had approved this year. In May 2009, the FDA approved EUR-1048, marketed by GlaxoSmithKline as Lamictal® ODT™ (lamotrigine) Orally Disintegrating Tablets. Like Paracetamol ODT, Lamictal ODT uses Eurand"s AdvaTab® orally disintegrating tablet (ODT) and Microcaps® taste-masking technologies. Eurand


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009